<DOC>
	<DOC>NCT02551809</DOC>
	<brief_summary>The purpose of this Phase IIa study is to determine whether the AD Immunotherapeutic Vaccine (UB-311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and immunogenic in mild AD patients. In addition, the efficacy profiles will be evaluated as the secondary endpoint.</brief_summary>
	<brief_title>Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of mild Alzheimer's Disease MiniMental State Examination (MMSE) scores between 20 and 26 (inclusive) Clinical dementia rating (CDR) scores of 0.5 or 1 Other inclusion criteria apply Clinically significant neurological disease other than Alzheimer's disease Major psychiatric disorder Severe systemic disease Serious adverse reactions to any vaccine Other exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>